Since the type of CD4+ T cell infiltrating the tumor can affect differently the prognosis of patients and the response to immunotherapy, epigenetic modulators can be used to induce appropriate CD4+ helper T cells polarization and recruitment in the TME. In this review, we presented recent literature showing the growing interest of combining epigenetic treatments with immunotherapy. The gene discussed is CD4; the disease is neoplasm.